Title
T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin
Date Issued
01 November 2017
Access level
open access
Resource Type
journal article
Author(s)
University of Rhode Island
Publisher(s)
Blackwell Publishing Ltd
Abstract
Background: Predicting vaccine efficacy against emerging pathogen strains is a significant problem in human and animal vaccine design. T-cell epitope cross-conservation may play an important role in cross-strain vaccine efficacy. While influenza A virus (IAV) hemagglutination inhibition (HI) antibody titers are widely used to predict protective efficacy of 1 IAV vaccine against new strains, no similar correlate of protection has been identified for T-cell epitopes. Objective: We developed a computational method (EpiCC) that facilitates pairwise comparison of protein sequences based on an immunological property—T-cell epitope content—rather than sequence identity, and evaluated its ability to classify swine IAV strain relatedness to estimate cross-protective potential of a vaccine strain for circulating viruses. Methods: T-cell epitope relatedness scores were assessed for 23 IAV HA sequences representing the major H1 swine IAV phylo-clusters circulating in North American swine and HA sequences in a commercial inactivated vaccine (FluSure XP®). Scores were compared to experimental data from previous efficacy studies. Results: Higher EpiCC scores were associated with greater protection by the vaccine against strains for 23 field IAV strain vaccine comparisons. A threshold for EpiCC relatedness associated with full or partial protection in the absence of cross-reactive HI antibodies was identified. EpiCC scores for field strains for which FluSure protective efficacy is not yet available were also calculated. Conclusion: EpiCC thresholds can be evaluated for predictive accuracy of protection in future efficacy studies. EpiCC may also complement HI cross-reactivity and phylogeny for selection of influenza strains in vaccine development.
Start page
531
End page
542
Volume
11
Issue
6
Language
English
OCDE Knowledge area
Bioquímica, Biología molecular
Virología
Scopus EID
2-s2.0-85035136752
PubMed ID
Source
Influenza and other Respiratory Viruses
ISSN of the container
17502640
Sponsor(s)
The authors gratefully acknowledge helpful discussions with Alan Rothman, Chris Bailey-Kellogg, Dennis Foss, Gail Skowron, and Ryan Tassone in the preparation of this manuscript.
Funding for this project was provided by University of Rhode Island and Zoetis Inc. VRG was employed by Zoetis Inc. at the time this study was conducted. ADG and WDM are senior officers and majority shareholders at EpiVax, Inc., a privately owned immunoinformatics and vaccine design company located in Providence, RI, USA. LM and FET are employees at EpiVax, in which LM holds stock options. ADG, WDM, LM, and FET acknowledge that there is a potential conflict of interest related to their relationship with EpiVax and attest that the work contained in this research report is free of any bias that might be associated with the commercial goals of the company. And while Zoetis scientists participated in the analysis of the results and provided vaccine/challenge outcomes information, the EpiCC analysis was performed independently by AHG, ADG, and LM, limiting the potential for commercial bias.
Sources of information:
Directorio de Producción Científica
Scopus